EUVIMEDEUVIMED entdecken
Crossref

Hepatitis E Virus in immunosuppressed patients in the era of global mobility

Susanne Gjeruldsen Dudman iD, Antonio Rivero-Juarez iD, Mia Blažević, Imran Hassanoglu, Nassim Kamar

Seminars in Liver Disease · 12.11.2026

DOI: 10.1055/a-2996-6521 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Seminars in Liver Disease, erschienen am 12.11.2026. Verfasst von Susanne Gjeruldsen Dudman und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Oslo, Institute of Clinical Medicine, Oslo, Norway, Oslo. Gefördert von: European Cooperation in Science and Technology.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatitis E virus (HEV) has emerged as a major, yet under-recognized, public health challenge worldwide, particularly in the context of increasing global mobility and expanding populations of immunosuppressed individuals. Zoonotic HEV, now the leading cause of acute viral hepatitis in Europe, is hindered by markedly heterogeneous surveillance systems, diagnostic strategies, and preventive policies, which limit cross-country comparability obscuring the true disease burden. Underdiagnosis is compounded by the existence of extrahepatic manifestations that escape conventional hepatotropic case definitions. At the same time, chronic HEV infection has gained clinical relevance among immunocompromised hosts, including solid organ transplant recipients, patients with hematologic malignancies, and those receiving biologic or other immunomodulatory therapies. However, the mechanisms driving viral persistence, progression to chronicity, and optimal antiviral management remain incompletely defined. This review synthesizes current epidemiological, clinical, and virological knowledge on HEV in Europe, with a focus on the implications of global migration, and the growing population at risk due to immunosuppression. It highlights key gaps and priority areas, particularly the management of infection in immunocompromised hosts and the development and implementation of targeted vaccination strategies for high-risk groups. In conclusion, integrated cross-disciplinary action is needed in response to this emerging threat.

Autor:innen und Institutionen

  • University of Oslo, Institute of Clinical Medicine, Oslo, Norway, Oslo.
  • Oslo University Hospital, Department of Microbiology, Oslo, Norway, Oslo.
  • Instituto Maimonides de Investigacion Biomedica de Cordoba, Clinical Virology and Zoonoses Research Group, Unit of Infectious Diseases, Spain, Córdoba.
  • Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Community of Madrid, Spain, Madrid.
  • Zavod Za Javno Zdravstvo Federacije Bosne I Hercegovine, Department of Communicable Disease Epidemiology, Institute for Public Health FB&H, Federation of Bosnia and Herzegovina, Bosnia and Herzegovina, Sarajevo.
  • Ministry of Health Ankara Bilkent City Hospital, Infectious Diseases and Clinical Microbiology, Ankara, Turkey, Çankaya.

ORCID-Profile: Susanne Gjeruldsen Dudman, Antonio Rivero-Juarez

Förderung

  • European Cooperation in Science and Technology

Zitieren

APA

Dudman, S. G., Rivero-Juarez, A., Blažević, M., Hassanoglu, I., & Kamar, N. (2026). Hepatitis E Virus in immunosuppressed patients in the era of global mobility. Seminars in Liver Disease. https://doi.org/10.1055/a-2996-6521

Vancouver

Dudman SG, Rivero-Juarez A, Blažević M, Hassanoglu I, Kamar N. Hepatitis E Virus in immunosuppressed patients in the era of global mobility. Seminars in Liver Disease. 2026. doi:10.1055/a-2996-6521

BibTeX
@article{Dudman2026,
  author = {Dudman, Susanne Gjeruldsen and Rivero-Juarez, Antonio and Blažević, Mia and Hassanoglu, Imran and Kamar, Nassim},
  title = {Hepatitis E Virus in immunosuppressed patients in the era of global mobility},
  journal = {Seminars in Liver Disease},
  year = {2026},
  doi = {10.1055/a-2996-6521}
}
Kostenlos starten →